国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2014年
8期
1112-1115
,共4页
多囊卵巢综合征%胰岛素抵抗%罗格列酮%排卵周期
多囊卵巢綜閤徵%胰島素牴抗%囉格列酮%排卵週期
다낭란소종합정%이도소저항%라격렬동%배란주기
Polycystic ovary syndrome (PCOS)%Insulin resistance (IR)%Rosiglitazone%Ovulation cycle
目的 分析罗格列酮对存在胰岛素抵抗(IR)的多囊卵巢综合征(PCOS)患者排卵周期的影响.方法 回顾性分析近两年来我院就诊并确诊为胰岛素抵抗的PCOS患者108例,分为三组:口服氯米芬组(A组)、口服罗格列酮组(B组)、口服氯米芬联合罗格列酮组(C组),用药三个月经周期,统计对比三组患者治疗前后胰岛素抵抗指数(HOMA-IR)、游离脂肪酸(FFA)、肿瘤坏死因子α(TNF-α)和有排卵周期例数变化的差异.结果 罗格列酮组和联合治疗组患者HOMAIR、FFA和TNF-α水平均明显降低,差异有统计学意义(P＜0.05),氯米芬组治疗前后差异无统计学意义;罗格列酮组患者有排卵周期例数增加,不显著,氯米芬组和联合治疗组有排卵周期例数明显增加,且组间比较联合治疗组增加幅度明显优于氯米芬组,差异有统计学意义(P＜0.05).结论 罗格列酮能有效改善胰岛素抵抗,对促排卵药氯米芬增加PCOS患者有排卵周期例数具有促进作用.
目的 分析囉格列酮對存在胰島素牴抗(IR)的多囊卵巢綜閤徵(PCOS)患者排卵週期的影響.方法 迴顧性分析近兩年來我院就診併確診為胰島素牴抗的PCOS患者108例,分為三組:口服氯米芬組(A組)、口服囉格列酮組(B組)、口服氯米芬聯閤囉格列酮組(C組),用藥三箇月經週期,統計對比三組患者治療前後胰島素牴抗指數(HOMA-IR)、遊離脂肪痠(FFA)、腫瘤壞死因子α(TNF-α)和有排卵週期例數變化的差異.結果 囉格列酮組和聯閤治療組患者HOMAIR、FFA和TNF-α水平均明顯降低,差異有統計學意義(P＜0.05),氯米芬組治療前後差異無統計學意義;囉格列酮組患者有排卵週期例數增加,不顯著,氯米芬組和聯閤治療組有排卵週期例數明顯增加,且組間比較聯閤治療組增加幅度明顯優于氯米芬組,差異有統計學意義(P＜0.05).結論 囉格列酮能有效改善胰島素牴抗,對促排卵藥氯米芬增加PCOS患者有排卵週期例數具有促進作用.
목적 분석라격렬동대존재이도소저항(IR)적다낭란소종합정(PCOS)환자배란주기적영향.방법 회고성분석근량년래아원취진병학진위이도소저항적PCOS환자108례,분위삼조:구복록미분조(A조)、구복라격렬동조(B조)、구복록미분연합라격렬동조(C조),용약삼개월경주기,통계대비삼조환자치료전후이도소저항지수(HOMA-IR)、유리지방산(FFA)、종류배사인자α(TNF-α)화유배란주기례수변화적차이.결과 라격렬동조화연합치료조환자HOMAIR、FFA화TNF-α수평균명현강저,차이유통계학의의(P＜0.05),록미분조치료전후차이무통계학의의;라격렬동조환자유배란주기례수증가,불현저,록미분조화연합치료조유배란주기례수명현증가,차조간비교연합치료조증가폭도명현우우록미분조,차이유통계학의의(P＜0.05).결론 라격렬동능유효개선이도소저항,대촉배란약록미분증가PCOS환자유배란주기례수구유촉진작용.
Objective To analyze the influence of rosiglitazone on ovulation of polycystic ovary syndrome(PCOS) patients with insulin resistance(IR).Methods 108 PCOS patients diagnosed with insulin resistance in our hospital during these two years were retrospectively analyzed.The patients were divided into three groups:group A orally took chlorine; group B rosiglitazone; and group C chlorine and rosiglitazone.These three groups were all treated for three menstrual cycles.The insulin resistance index (HOMA IR),free fatty acid (FFA),tumor necrosis factor alpha (TNF alpha),and the number of ovulation cycle of the 3 groups before and after the treatment were statistically analyzed and compared.Results The HOMA IR,FFA,and TNF alpha levels of group B and group C were significantly lower,with statistical differences(P ＜ 0.05).However,there was no statistical difference in group A before and after the treatment.There were no significant increases in the number of ovulation cycle in group A; while both group B and group C significantly increased in the number of ovulation cycles.The increased number of group C is obviously more than that of group B,with statistical difference(P ＜ 0.05).Conclusions Rosiglitazone can effectively improve insulin resistance and has promoting effect to the ovulation cycle of the PCOS patients with IR.
